Key result
Target-specific oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, are at least as efficacious as dose-adjusted warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Why the study?
Do target-specific oral anticoagulants prevent stroke or systemic embolism in patients with nonvalvular atrial fibrillation compared to vitamin K antagonists?
Population
Patients with nonvalvular atrial fibrillation
Comparison
Target-specific oral anticoagulants vs Vitamin K antagonists (dose-adjusted warfarin)
Design
Review
Authors
Loading...
Supports target-specific oral anticoagulants for stroke prevention in nonvalvular AF; leaves open patient-specific optimization in real-world use.
Do target-specific oral anticoagulants prevent stroke or systemic embolism in patients with nonvalvular atrial fibrillation compared to vitamin K antagonists?
Target-specific oral anticoagulants are effective alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation, but require careful consideration of patient-specific factors like renal function, age, and drug interactions.
Undas et al. (2014) conducted a review in nonvalvular atrial fibrillation. Target-specific oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Vitamin K antagonists (warfarin) was evaluated. Target-specific oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, are at least as efficacious as dose-adjusted warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: